Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Receivables: 2020-2023

Historic Receivables for Rocket Pharmaceuticals (RCKT) over the last 2 years, with Dec 2023 value amounting to $50,000.

  • Rocket Pharmaceuticals' Receivables was N/A to $50,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $50,000 for FY2023, which is N/A change from last year.
  • Rocket Pharmaceuticals' Receivables amounted to $50,000 in FY2023, which was down 95.45% from $1.1 million recorded in FY2020.
  • Over the past 5 years, Rocket Pharmaceuticals' Receivables peaked at $1.1 million during FY2020, and registered a low of $50,000 during FY2023.
  • Over the past 1 years, Rocket Pharmaceuticals' median Receivables value was $50,000 (recorded in 2023), while the average stood at $50,000.